ClinicalTrials.gg
CompletedNCT06942299Updated Apr 24, 2025

A Study of AK0529 in Adults Patients Hospitalized With RSV Infection

A Phase 2 interventional study of AK0529 and AK0529 in Respiratory Syncytial Virus Infections, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 42 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Enrollment
20th of 25
25 · median 132
Started
2023
with 6 others
Phase 2
6 of 30
1 open now
Registered
9th of 30
by date
Lead sponsor
4 of 30
Shanghai Ark Biopharmaceutical Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2023, is one of 6 in phase 2, and was the 9th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter, phase II study to be conducted in adults hospitalized with RSV infection in China. The main objectives of this study are to investigate the safety, pharmacokinetics and efficacy of AK0529 in adult RSV patients.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Adult patient with RSV infection
  • High-risk disease
  • AK0529
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion criteria:

  1. . Male or female patients of any ethnicity with an age of 18-85 years.
  2. . Diagnosis of RSV infection by any virological means within 36 hours preceding initial dosing.
  3. . At least one of the following high-risk diseases or states for RSV infection

    1. Asthma or chronic lung disease (such as or cystic fibrosis),
    2. ,
    3. Heart disease (such as congenital heart disease, congestive, heart failure, or coronary artery disease), except high blood, pressure without heart-related symptoms,
    4. Chronic kidney disease,
    5. Age ≥65 years old.
  4. . With at least 1 new onset respiratory infection symptom or exacerbation of existing respiratory symptoms (respiratory symptoms include: sore throat, nasal congestion, runny nose, sneezing, coughing, wheezing, sputum production, shortness of breath), and any individual score is 2 or moderate.
  5. . Onset of RSV infection symptoms should be ≤ 7 days.

Main Exclusion criteria:

  1. . 3 days for drugs with potential antiviral effects on RSV such as ordinary interferon, 8 days for long-acting interferon, and 35 days for ribavirin for 5 half-lives before expected administration.
  2. . Prohibited medicine are being used or planned to be used during the study treatment periods.
  3. . Severe gastrointestinal diseases that affect the absorption of study drugs (such as vomiting, malabsorption syndrome, short bowel syndrome due to necrotizing enterocolitis, etc.).
  4. . Received or planned to have bone marrow transplantation, stem cell transplantation or solid organ transplantation within 1 year.
  5. . Patients with malignant tumors who had surgery within recent 6 months and/or requiring radiotherapy, chemotherapy and biological immunotherapy.
  6. . Patients with diseases who are in the induction treatment.
  7. . infection, \< 350 cells/mm3 with opportunistic infection and need treatment.
  8. . Other patients who are judged by the investigator to be unsuitable for participating in the study, such as acute/chronic heart, lung, liver, kidney, rheumatic immunity, psychiatric, blood and other diseases in the unstable period.
  9. . History of drug abuse within 12 months prior to screening.
  10. . Allergy to the drug or its component.
  11. . Female patients with positive pregnancy test or breastfeeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Active drug: AK0529 fasting

    The participants will receive AK0529 twice daily for 5 days from D1 to D5.

    Drug: AK0529

  • Experimental
    Active drug: AK0529 with meal

    The participants will receive AK0529 twice daily for 5 days from D1 to D5.

    Drug: AK0529

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugAK0529

    Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral, fasting

  • DrugAK0529

    Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral with meal

  • DrugPlacebo

    Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral with meal or fasting

06

What researchers measure

Primary outcomes

  1. Incidence and severity of AE and SAE of subjects during the study period

    An Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect, or another important medical event.

    Time frame: Baseline up to 28 days

Secondary outcomes

  1. Change from baseline in clinical improvement score of subjects at each visit after treatment by clinical improvement scale

    Clinical improvement scale is mainly used to evaluate the overall severity level of the subject's disease with the highest score of 8 indicating death. A score of 6-7 represents severe hospitalization: a score of 6 requires mechanical ventilation, and a score of 7 requires not only mechanical ventilation but also angiogenic treatment, kidney dialysis, or artificial membrane lung. A score of 3-5 represents mild hospitalization: a score of 3 does not require oxygen therapy, a score of 4 requires a mask or nasal catheter, and a score of 5 requires noninvasive positive pressure ventilation or high-flow oxygen therapy. A score of 1-2 represents outpatient treatment: 1 is independent and 2 is in need of care (daily activities have an impact). A score of 0 means no treatment is required and there is no clinical or virological evidence of infection.

    Time frame: Baseline up to 28 days

  2. Change from baseline in RiiQ symptoms of subjects at each visit after treatment measured by RiiQ questionnaire

    RiiQ questionnaire is mainly used to assess RSV symptoms in patients, including upper respiratory tract infection symptoms (sore throat and nasal congestion), symptoms of lower respiratory tract infection (cough, wheezing, sputum, shortness of breath), and system symptoms (fever, headache, neck pain, fatigue, lack of appetite, interrupted sleep, body aches). The questionnaire is divided into four grading categories of severity including none (0), mild (1), moderate (2) and severe (3).

    Time frame: Baseline up to 28 days

  3. Changes from baseline in the total score of RSV Symptom of subjects at each visit after treatment using RSV Symptom Score Composite Scale

    RSV Symptom Score Composite Scale is used to assess patients with RSV symptoms, including runny nose, stuffy nose, sneezing, sore throat, earache, cough, shortness of breath, headache, fatigue, myalgia and/or joint pain. The score is divided into 4 grades according to the severity of symptoms. 0 indicates no symptoms, 1 indicates occasional symptoms, 2 indicates that symptoms sometimes worsen significantly but do not affect daily activities, and 3 indicates that symptoms are always serious and cannot engage in daily activities. The total score is 30 points.

    Time frame: Baseline up to 28 days

  4. Changes from baseline in the RSV VL (viral load) of subjects at each visit after treatment

    The RSV VL of subjects' nasopharyngeal samples is measured as Log10 copies/mL by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

    Time frame: Baseline up to 28 days

  5. Area under the curve (AUCE, last) of RSV Viral Load from baseline to the last measurement

    The RSV VL is measured as Log10 copies/mL by qRT-PCR assay in the nasopharyngeal specimens.

    Time frame: Baseline up to 28 days

  6. Number of subjects with RSV VL values below the lower limit of quantitation (LLOQ) at each visit after treatment

    The RSV VL is measured as Log10 copies/mL by qRT-PCR assay in the nasopharyngeal specimens.

    Time frame: Baseline up to 28 days

  7. Number of participants who dropped out of the study due to AE

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Time frame: Baseline up to 28 days

  8. Number of participants with laboratory examination abnormalities

    Following parameters were analyzed for laboratory examination: hemoglobin (Hb), hematocrit, platelet count, red blood cell (RBC) count, white blood cell (WBC) count, mean corpuscular volume (MCV) and absolute white blood cell line (neutrophils, eosinophils, lymphocytes, monocytes, basophils); Hepatobiliary biochemistry: total and direct bilirubin, total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP); Renal Function Tests: creatinine kinase, uric acid ; Electrolytes: Sodium, Potassium; Glucose; Coagulation function (subjects with only a history of liver disease should be tested): international normalized ratio (INR), activated partial thromboplastin time, prothrombin time, thrombin time, and fibrinogen; Urine analysis: urine protein, ketone bodies, urine red blood cells, urine white blood cells, and urine glucose; Blood or urine pregnancy test for all female subjects.

    Time frame: Baseline up to 28 days

  9. Number of participants with vital sign abnormalities

    Number of participants with vital sign (systolic and diastolic blood pressure, pulse rate, respiratory rate, temperature and oxygen saturation) abnormalities were reported.

    Time frame: Baseline up to 28 days

  10. Number of participants with physical examination abnormalities

    A comprehensive physical examination includes at least cardiovascular, respiratory, gastrointestinal, and nervous system assessments; a simple physical examination includes at least skin, lung, cardiovascular system and abdominal (liver and spleen) assessments.

    Time frame: Baseline up to 28 days

  11. Number of participants with ECG abnormalities

    Electrocardiograms were measured during the screening period, at 4 (±1) hours after the first dose on day 2, at 4 (±1) hours and 12 (±1) hours (before the second dose) after the first dose on day 4, and once on day 6 and day 14 during the follow-up period; 9-or 12-lead ECG results are recorded using an ECG instrument which automatically calculates heart rate and measures PR, QRS, QT and QTc intervals.

    Time frame: Baseline up to 28 days

  12. Peak Plasma Concentration (Cmax)

    Whole blood of subjects (2 mL per time point) was collected for the concentration determination of the AK0529 and its metabolites at various time points on day 1 and day 5, and the PK parameter is calculated using the above-mentioned plasma concentration data.

    Time frame: Day 1, Day 5

  13. Time to Maximum Plasma Concentration (Tmax)

    Whole blood of subjects (2 mL per time point) was collected for the concentration determination of the AK0529 and its metabolites at various time points on day 1 and day 5, and the PK parameter is calculated using the above-mentioned plasma concentration data.

    Time frame: Day 1,Day 5

  14. Terminal Elimination Half-life (t½)

    Whole blood of subjects (2 mL per time point) was collected for the concentration determination of the AK0529 and its metabolites at various time points on day 1 and day 5, and the PK parameter is calculated using the above-mentioned plasma concentration data.

    Time frame: Day 1,Day 5

  15. Apparent Clearance (CL/F)

    Whole blood of subjects (2 mL per time point) was collected for the concentration determination of the AK0529 and its metabolites at various time points on day 1 and day 5, and the PK parameter is calculated using the above-mentioned plasma concentration data.

    Time frame: Day 1,Day 5

  16. Apparent Volume of Distribution (V[z]/F)

    Whole blood of subjects (2 mL per time point) was collected for the concentration determination of the AK0529 and its metabolites at various time points on day 1 and day 5, and the PK parameter is calculated using the above-mentioned plasma concentration data.

    Time frame: Day 1,Day 5

  17. Area Under the Plasma Concentration-Time Curve From Time 0 to 12 (AUC[0-12])

    Whole blood of subjects (2 mL per time point) was collected for the concentration determination of the AK0529 and its metabolites at various time points on day 1 and day 5, and the PK parameter is calculated using the above-mentioned plasma concentration data.

    Time frame: Day 1,Day 5

  18. Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC[0-∞])

    Whole blood of subjects (2 mL per time point) was collected for the concentration determination of the AK0529 and its metabolites at various time points on day 1 and day 5, and the PK parameter is calculated using the above-mentioned plasma concentration data.

    Time frame: Day 1,Day 5

07

Study locations

42 sites
  • The Second Perople's Hospital of Hefei
    Hefei, Anhui, China
  • Huangshan City People's Hospital
    Huangshan, Anhui, China
  • Peking University Shougang Hospital
    Beijing, Beijing 100000, China
  • Beijing Hospital
    Beijing, Beijing 100005, China
  • China-Japan Friendship Hospital
    Beijing, Beijing 100029, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350004, China
  • Quanzhou First Hospital
    Quanzhou, Fujian, China
  • Gansu People's Hospital
    Lanzhou, Gansu, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • Guangzhou Panyu Central Hospital
    Guangzhou, Guangdong 511486, China
  • Longgang Central Hospital of Shenzhen
    Shenzhen, Guangdong 518116, China
  • Shunde Hospital of Southern Medical University
    Shunde, Guangdong 528399, China
  • Central People's Hospital of Zhanjiang
    Zhanjiang, Guangdong 524037, China
  • The Second Nanning People's Hospital
    Nanning, Guangxi, China
  • Guizhou People's Hospital
    Guiyang, Guizhou, China
  • Hebei Chest Hospital
    Shijiazhuang, Hebei, China
  • Harbin Medical University Affiliated Fourth Hospital
    Ha'erbin, Heilongjiang, China
  • The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine
    Ha'erbin, Heilongjiang, China
  • The Sixth People's Hospital of Zhengzhou
    Zhengzhou, Henan, China
  • Wuhan Fourth Hospital
    Wuhan, Hubei, China
  • Xiangyang Center Hospital
    Xiangyang, Hubei, China
  • Yueyang Central Hospital
    Yueyang, Hunan, China
  • Changzhou Second People's Hospital
    Changzhou, Jiangsu 213004, China
  • Jiangsu Provincial Hospital of Chinese Medicine
    Nanjing, Jiangsu 210004, China
  • The First Affilited Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Jilin Province People's Hospital
    Changchun, Jilin, China
  • The First Clinical College / Liaoning Hospital of TCM
    Shenyang, Liaoning, China
  • Inner Mongolia Autonomous Region People's Hospital
    Hohhot, Neimenggu, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • Weifang NO.2 People's Hospital
    Weifang, Shandong, China
  • Tongji Hospital of Tongji University
    Shanghai, Shanghai 200065, China
  • Yueyang Hospital Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai 200437, China
  • Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai 201203, China
  • Sencond Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • The First Affiliated Hospital of Xi'an Medical University
    Xi'an, Shanxi, China
  • Chengdu Seventh People's Hospital
    Chendu, Sichuan 610044, China
  • The First Hospital of Kunming
    Kunming, Yunnan, China
  • The First People's Hospital of Yunnan Province
    Kunming, Yunnan, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 314408, China
  • Ningbo First Hospital
    Ningbo, Zhejiang 315010, China
  • Shaoxing People's Hospital
    Shaoxing, Zhejiang 312035, China
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang 317099, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2024, 11 months.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 11 months is close to that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2023
First posted
Apr 24, 2025
StartActual
Jul 20, 2023
Primary completionActual
Jun 28, 2024
CompletionActual
Jun 28, 2024
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942299
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Jul 20, 2023
Primary completion
Jun 28, 2024
Completion
Jun 28, 2024
Last update
Apr 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion